Literature DB >> 19649989

Adeno-associated virus vector integration.

David R Deyle1, David W Russell.   

Abstract

Adeno-associated virus (AAV) vectors efficiently transduce various cell types and can produce long-term expression of transgenes in vivo. Although AAV vector genomes can persist within cells as episomes, vector integration has been observed in various experimental settings, either at non-homologous sites where DNA damage may have occurred or by homologous recombination. In some cases, integration is essential for the therapeutic or experimental efficacy of AAV vectors. Recently, insertional mutagenesis resulting from the integration of AAV vectors was associated with tumorigenesis in mice, a consideration that may have relevance for certain clinical applications.

Entities:  

Mesh:

Year:  2009        PMID: 19649989      PMCID: PMC2929125     

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  79 in total

Review 1.  Strategies to maintain the stability of the ribosomal RNA gene repeats--collaboration of recombination, cohesion, and condensation.

Authors:  Takehiko Kobayashi
Journal:  Genes Genet Syst       Date:  2006-06       Impact factor: 1.517

2.  The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage.

Authors:  Peng Wang; Jian Yu; Lin Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-28       Impact factor: 11.205

3.  Gene targeting in vivo by adeno-associated virus vectors.

Authors:  Daniel G Miller; Pei-Rong Wang; Lisa M Petek; Roli K Hirata; Mark S Sands; David W Russell
Journal:  Nat Biotechnol       Date:  2006-07-30       Impact factor: 54.908

4.  Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver.

Authors:  Peter Bell; A David Moscioni; Robert J McCarter; Di Wu; Guangping Gao; Albert Hoang; Julio C Sanmiguel; Xun Sun; Nelson A Wivel; Steven E Raper; Emma E Furth; Mark L Batshaw; James M Wilson
Journal:  Mol Ther       Date:  2006-05-06       Impact factor: 11.454

5.  Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.

Authors:  Jung-Sik Kim; Carolyn Lee; Challice L Bonifant; Habtom Ressom; Todd Waldman
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

Review 6.  Primate segmental duplications: crucibles of evolution, diversity and disease.

Authors:  Jeffrey A Bailey; Evan E Eichler
Journal:  Nat Rev Genet       Date:  2006-06-13       Impact factor: 53.242

7.  Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation.

Authors:  P J Hurley; D Wilsker; F Bunz
Journal:  Oncogene       Date:  2006-10-16       Impact factor: 9.867

8.  Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.

Authors:  Eike Gallmeier; Eric S Calhoun; Carlo Rago; Jonathan R Brody; Steven C Cunningham; Tomas Hucl; Myriam Gorospe; Manu Kohli; Christoph Lengauer; Scott E Kern
Journal:  Gastroenterology       Date:  2006-06       Impact factor: 22.682

9.  Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss.

Authors:  Steven C Cunningham; Eike Gallmeier; Tomas Hucl; David A Dezentje; Eric S Calhoun; Geppino Falco; Kotb Abdelmohsen; Myriam Gorospe; Scott E Kern
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

10.  Homologous recombination is required for AAV-mediated gene targeting.

Authors:  Ana Vasileva; R Michael Linden; Rolf Jessberger
Journal:  Nucleic Acids Res       Date:  2006-07-05       Impact factor: 16.971

View more
  82 in total

Review 1.  Combining CRISPR/Cas9 and rAAV Templates for Efficient Gene Editing.

Authors:  Manuel Kaulich; Steven F Dowdy
Journal:  Nucleic Acid Ther       Date:  2015-11-05       Impact factor: 5.486

2.  Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease.

Authors:  Christian M Brommel; Ashley L Cooney; Patrick L Sinn
Journal:  Hum Gene Ther       Date:  2020-08-21       Impact factor: 5.695

3.  Gene transfer into cardiac myocytes.

Authors:  Sarah E Lang; Margaret V Westfall
Journal:  Methods Mol Biol       Date:  2015

4.  AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS.

Authors:  Marcel F Leyton-Jaimes; Joy Kahn; Adrian Israelson
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-01       Impact factor: 11.205

5.  A largely random AAV integration profile after LPLD gene therapy.

Authors:  Christine Kaeppel; Stuart G Beattie; Raffaele Fronza; Richard van Logtenstein; Florence Salmon; Sabine Schmidt; Stephan Wolf; Ali Nowrouzi; Hanno Glimm; Christof von Kalle; Harald Petry; Daniel Gaudet; Manfred Schmidt
Journal:  Nat Med       Date:  2013-06-16       Impact factor: 53.440

Review 6.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

Review 7.  AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects.

Authors:  Zongchao Han; Shannon M Conley; Muna I Naash
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-10       Impact factor: 4.799

Review 8.  State-of-the-art gene-based therapies: the road ahead.

Authors:  Mark A Kay
Journal:  Nat Rev Genet       Date:  2011-04-06       Impact factor: 53.242

Review 9.  Advances in Alpha-1 Antitrypsin Gene Therapy.

Authors:  Reka Lorincz; David T Curiel
Journal:  Am J Respir Cell Mol Biol       Date:  2020-11       Impact factor: 6.914

Review 10.  A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme.

Authors:  Thomas Wirth
Journal:  World J Exp Med       Date:  2011-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.